Harrow, Inc. · NASDAQ:HROW

Harrow — Imprimis Pharmaceuticals — Q2 2017 Earnings Presentation

7 slides from Harrow's earnings presentation, Aug 28, 2017

1. Slide 1: Slide 1

2. Slide 2: Investment Highlights

   imprimis PHARMACEUTICALS Q2-2017 | NASDAQ: IMMY OEE Investment Highlights Ophthalmology-focused pharmaceutical company with commercial products in the three largest U.S. ophthalmic markets 13 consecutive quarters of double digit or better year over year revenue growth Q2-2017 Net Income: $1.5M Gross

3. Slide 3: Slide 3

4. Slide 4: Slide 4

5. Slide 5: Cataract / LASIK — Since 2014

   Cataract / LASIK — Since 2014 Cost, call back and compliance are some of the most common complaints for post-cataract and LASIK procedure care. By utilizing SSP Technology, our patent-pending Dropless and LessDrops formulations address these issues. , =} a Tiamcinotone Ace Voxifloxacin HCl '8i1}mgim

6. Slide 6: Slide 6

7. Slide 7: Slide 7

Imprimis Pharmaceuticals — Q2 2017 Earnings Presentation on 6ix